

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

The effects of combined zinc and magnesium supplementation on metabolic profiles and gene expression related to insulin and lipid in women with polycystic ovary syndrome

Protocol summary

Study aim

Objective: The aim of this study is to determine the effects of combined magnesium and zinc supplementation on metabolic profiles and gene expression related to insulin and lipid in women with polycystic ovary syndrome

Design

Study design: Randomized double-blind placebo-controlled trial, All participants will have stratified randomization according to BMI (<25 and \geq 25 kg/m²) and age (<30 and \geq 30 y). Then, participants in each block will be randomly allocated into two groups. Randomization will be done by the use of computer software.

Settings and conduct

Among patients with polycystic ovary syndrome referred to Naghavi outpatient Clinic affiliated to Kashan University of Medical Sciences, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups. Supplements and placebos are similar in shape and size. Fasting blood samples will be taken at baseline and 12 weeks after the intervention. At the beginning and the end of the intervention: 12 weeks

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with polycystic ovary syndrome aged 18 to 40 years. Exclusion criteria: Individuals with androgen-secreting tumors, CVD and diabetes, thyroid dysfunction, and pregnant women.

Intervention groups

Intervention group: 250 mg magnesium oxide (21st Century, Arizona, USA) + 220 mg of zinc sulfate (Alhavi Pharmaceutical Company, Tehran, Iran) daily, for 12 weeks orally. Control group: Placebo, daily, for 12 weeks orally.

Main outcome variables

Outcomes: Markers of insulin metabolism (primary outcomes) and lipid profiles and gene expression related to insulin and lipid (secondary outcomes) will be quantified at study baseline and end-of-trial.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20170513033941N40**

Registration date: **2018-10-31, 1397/08/09**

Registration timing: **retrospective**

Last update: **2019-09-15, 1398/06/24**

Update count: **1**

Registration date

2018-10-31, 1397/08/09

Registrant information

Name

Mohammadreza Sharif

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 5546 3378

Email address

ostadmohammadi-vr@kaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-07-31, 1397/05/09

Expected recruitment end date

2018-08-15, 1397/05/24

Actual recruitment start date

empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
The effects of combined zinc and magnesium supplementation on metabolic profiles and gene expression related to insulin and lipid in women with polycystic ovary syndrome

Public title
Effect of combined zinc and magnesium supplementation in treatment of women with polycystic ovary syndrome

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Patients with polycystic ovary syndrome Individuals aged 18 to 40 years.
Exclusion criteria:
Androgen-secreting tumors cardiovascular diseases and diabetes Pregnant women Thyroid dysfunction

Age
From **18 years** old to **40 years** old

Gender
Female

Phase
3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor

Sample size
Target sample size: **60**

Randomization (investigator's opinion)
Randomized

Randomization description
To decrease potential confounding effects, all participants will have stratified randomization according to BMI (<25 and ≥25 kg/m²) and age (<30 and ≥30 y). Then, participants in each block will be randomly allocated into two treatment groups to take either supplements or placebo. Randomization will be done by the use of computer software.

Blinding (investigator's opinion)
Double blinded

Blinding description
Randomization and allocation will be concealed from the researchers and participants until the final analyses are completed. Another person at Naghavi outpatient clinic, who is not involved in the trial and not aware of random sequences, will be assigned the participants to the numbered bottles of capsules

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kashan University of Medical Sciences

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

1771844351

Approval date

2018-07-30, 1397/05/08

Ethics committee reference number

IR.KAUMS.MEDNT.REC.1397.026

Health conditions studied

1

Description of health condition studied

Polycystic ovary syndrome

ICD-10 code

E28.2

ICD-10 code description

Polycystic ovarian syndrome

Primary outcomes

1

Description

Insulin resistance

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Calculation using HOMA formula

2

Description

Insulin

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Elisa kit

Secondary outcomes

1

Description

Total cholesterol

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Enzymatic kit

2

Description

HDL

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

Enzymatic kit

3

Description

Triglycerides

Timepoint

At the beginning of the study and after 12 weeks of intervention Triglycerides

Method of measurement

Enzymatic kit

4

Description

Expressed levels of PPAR- γ gene

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

PCR

5

Description

Expressed levels of GLUT-1 gene

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

PCR

6

Description

Expressed levels of LDL-R gene

Timepoint

At the beginning of the study and after 12 weeks of intervention

Method of measurement

PCR

Intervention groups

1

Description

Intervention group: 250 mg magnesium oxide (21st Century, Arizona, USA) + 220 mg of zinc sulfate (Alhavi Pharmaceutical Company, Tehran, Iran) daily, for 12 weeks orally

Category

Treatment - Drugs

2

Description

Control group: Placebo, daily, for 12 weeks orally.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Naghavi outpatient Clinic

Full name of responsible person

Dr. Fatemeh Foroozafard

Street address

Shahid Rajaei Avenue, Kashan

City

Kashan

Province

Isfahan

Postal code

1771844351

Phone

+98 31 5546 3378

Email

forozaifar_f@kaums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Kashan University of Medical Sciences

Full name of responsible person

Gholamali Hamidi

Street address

Ghotbe Ravandi Boulevard, Kashan

City

Kashan

Province

Isfahan

Postal code

1771844351

Phone

+98 31 5546 3378

Email

Gholamali_h@kaums.ac.ir

Grant name

Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice chancellor for research, Kashan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
PhD of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfahan
Postal code
1771844351
Phone
+98 31 5546 3378
Fax
Email
asemi_z@kaums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
PhD of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address

Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfahan
Postal code
1771844351
Phone
+98 31 5546 3378
Fax
Email
asemi_z@kaums.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
PhD of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfahan
Postal code
1771844351
Phone
+98 31 5546 3378
Fax
Email
asemi_z@kaums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available